Member Info for moonparty

Kashdog, a1's 'point' is fairly transparent, we can all see what he's posted and infer the motive

Autonomy1, honestly, you should sell up and run away.
Don't buy without researching first! Not surprised you are not making money.
Most regulars here HAVE researched Scancell and have held for years because they can see how good the tech is. And it all seems to be happening for Scancell right now.

I think the N protein must be much more difficult to target, not from any scientific knowledge, but the fact that ALL of the early vaccines target the spike protein. Presumably because it is quick and easy and there are/were off-the-shelf technologies to do it? (when I say quick and easy I mean relatively, appreciate it was still a massive achievement)

With respect hasiba, nobody invests in a biotech, long term at least, without the expectation of the possibility of 10x, 20x, 50x. That's the nature of the game - many fail, but those that succeed succeed big.
That's why the research, in scientific terms, is so important before jumping in. Obviously you need a good management team, funding, contacts and a bit of luck to pull it off, but without solidity in the basic science (nd protection of the technology via IP) then you probably ARE looking at a lifestyle company.
There are dozens of long-term holders here who have done their homework and verified that Scancell have something above and beyond other companies.
A lot of us may come across as smug, and you are right to doubt overwhelmingly bullish posters, but we are not just 'talking up our book', we have spent 100's of hours researching and looking for the 'gotcha' with the science and come to the same conclusion - Scancells tech is paradigm shifting and just works.
I certainly sleep easy with a large percentage of my portfolio in Scancell.

I agree with most of what you say hasiba, though I think the research to develop ground breaking science can be long and painful, however much resource you throw at it.
However, Scancell already have many partnerships - BionTech, Karolinska, UoN to name 3, and probably others I have forgotten about.
They are also in development partnerships with at least 3 large pharma's on Avidimab.
It is frustrating that none have, yet, led to commercialisation, but we do seem to be very close on so many fronts...

Compare Scancell with other bio's on AIM or other markets, and the market cap looks ridiculously small IMO.
I'm not going to mention others as I'll get in trouble, but I actually hold other bio's that have a higher market cap, less cash and, IMO, less prospects. (something about diversification, apparently it's sensible!).
Scancell have the runway of a large pharma for a small pharma market cap. It's inconceivable the 'end game' (whatever form that may take) will result in a bad return from this price. We have already been guided by Scancell not to expect news until Q2, which we are only in the first month of, so news is NOT overdue. I've been accumulating not reducing, though it feels weird to be buying and increasing my average price, lol.

Lol. Let's go with somewhere between those 2 dates!

My theory is
Last news 10/3
Next news 21/4

Just add one to each digit. Simples :)

"I'll take credit for the middle one - was going to split between SCLP and AGL but decided to put it all in SCLP."
Well I got that wrong :(
Good to see AGL doing well though.
Actual spread is 22.60/23 from my dummy buy/sell of 50K

I'll take credit for the middle one - was going to split between SCLP and AGL but decided to put it all in SCLP.

Well I've bought a few more, thankfully after the drop to 22/23p.
Good news tomorrow morning please !

I have this years cash in my ISA, some of which is destined for Scancell.
I'm hesitating though - normally when I buy, the price immediately goes down :(

Sadly there is no obvious mechanism for mutations getting less lethal. Ordinarily if a virus kills a large proportion of its hosts it will become less dominant then those that don't kill or kill a smaller proportion of their hosts. Basic natural selection - if they kill the thing that sustains them there is nowhere to go. And also, if a virus is very deadly humans get scared and take precautions.
But when it only kills a very small proportion of its hosts, and crucially, is a relatively mild illness in most cases, the mechanism for it getting less deadly does not exist.
This is what makes it so dangerous.

So much is on the short term horizon for Scancell, I'm really looking forward to the next few weeks of news.
Right time, right product, right place, right team, right contacts.

Thanks Cars, I'm already invested in an Australian Gold miners / explorer - have a sizeable sum in Calidus (CAI).
Always hold some gold as insurance they say, but it's too dull for me, so gold miners are the way to go!

Have to ask, what's the punt on?

On or around 25th March, year end results to be announced. Also expect director purchase announcements shortly afterwards as the close period will be over.
Should help the share price along a bit.
There were also hints about news post Nasdaq listing in the placing RNS. I expect the listing and placing will help finalise releasable news items, so IMO decent news flow in the next couple of weeks.

Price back up to 12.91 now on nasdaq. There is a vey wide spread and the price reported is the last traded, so it will seem volatile. Nothing to worry about. The volume is still in the UK.

But a percentage, of those vaccinated in trials and in the immunisation roll-out, will have been in contact with the coronavirus subsequently, and these adverse reactions haven't happened.
"against whatever is the real mRNA in the vaccines" doesn't make sense - we know what the "real mRNA" is in the vaccines, because we built the vaccines.
It sounds like a conspiracy theory that the vaccines contain something we haven't been told about. Best ignored.

I don't understand - the current vaccine(s) were tested and there were no deaths attributable to the vaccine, so whatever the theory was behind this prediction it is clearly misguided ?